- Home
- GILT vs BMEA Comparison
GILT vs BMEA Comparison
Compare GILT & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILT
- BMEA
- Stock Information
- Founded
- GILT 1987
- BMEA 2017
- Country
- GILT Israel
- BMEA United States
- Employees
- GILT N/A
- BMEA N/A
- Industry
- GILT Radio And Television Broadcasting And Communications Equipment
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- GILT Technology
- BMEA Health Care
- Exchange
- GILT Nasdaq
- BMEA Nasdaq
- Market Cap
- GILT 381.2M
- BMEA 65.8M
- IPO Year
- GILT 1993
- BMEA 2021
- Fundamental
- Price
- GILT $7.21
- BMEA $1.67
- Analyst Decision
- GILT Strong Buy
- BMEA Strong Buy
- Analyst Count
- GILT 2
- BMEA 10
- Target Price
- GILT $8.50
- BMEA $22.30
- AVG Volume (30 Days)
- GILT 417.6K
- BMEA 2.3M
- Earning Date
- GILT 08-06-2025
- BMEA 07-30-2025
- Dividend Yield
- GILT N/A
- BMEA N/A
- EPS Growth
- GILT N/A
- BMEA N/A
- EPS
- GILT 0.24
- BMEA N/A
- Revenue
- GILT $321,407,000.00
- BMEA N/A
- Revenue This Year
- GILT $42.88
- BMEA N/A
- Revenue Next Year
- GILT $13.26
- BMEA N/A
- P/E Ratio
- GILT $30.05
- BMEA N/A
- Revenue Growth
- GILT 13.49
- BMEA N/A
- 52 Week Low
- GILT $4.04
- BMEA $1.29
- 52 Week High
- GILT $8.05
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- GILT 68.49
- BMEA 42.36
- Support Level
- GILT $6.94
- BMEA $1.63
- Resistance Level
- GILT $7.33
- BMEA $3.08
- Average True Range (ATR)
- GILT 0.24
- BMEA 0.23
- MACD
- GILT 0.08
- BMEA -0.08
- Stochastic Oscillator
- GILT 90.48
- BMEA 5.33
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.